Home Online Features Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study
Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study
Press Releases
Artax Biopharma  
January 22, 2025

Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study

Novel breakthrough: first molecule to modulate the fundamental mechanism of T cell activation underlying autoimmune pathology

logo salamanca press

Salamanca Press

email salamanca press
Local & Social